Posted On: 01/24/2015 1:05:07 PM
Post# of 30066
Here is some dot connecting to think about-
Jeffrey L. Cummings, M.D., Sc.D.
Cummings is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio.
is on the same ACT-AD Science Advisory Board as
Russell Katz, M.D.
Katz is the former director of the Division of Neurology Products for the U.S. Food and Drug Administration.
Gerald has used his quote a couple of times in PR's
"The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients." We believe this reinforces the need and desire for early-stage detection, and the potential multi-hundred million dollar opportunity that LymPro represents."
Also, if anyone remembers "Dr. Jerry" he is a neurologist in the Cleveland Clinic.
Jeffrey L. Cummings, M.D., Sc.D.
Cummings is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio.
is on the same ACT-AD Science Advisory Board as
Russell Katz, M.D.
Katz is the former director of the Division of Neurology Products for the U.S. Food and Drug Administration.
Gerald has used his quote a couple of times in PR's
"The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain. It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients." We believe this reinforces the need and desire for early-stage detection, and the potential multi-hundred million dollar opportunity that LymPro represents."
Also, if anyone remembers "Dr. Jerry" he is a neurologist in the Cleveland Clinic.
(0)
(0)
